Soleus Capital Management »

Sab Biotherapeutics shares owned by Soleus Capital Management

Quarter-by-quarter ownership of Sab Biotherapeutics (SABS) shares owned by Soleus Capital Management from 13F filings

Historical chart of Soleus Capital Management investment in Sab Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sab Biotherapeutics held by Soleus Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sab Biotherapeutics by Soleus Capital Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $4.0M 1.1M 3.83

More positions owned by Soleus Capital Management

Krystal Biotech (KRYS)
Celcuity (CELC)
Tg Therapeutics (TGTX)
Insulet Corporation (PODD)
Novocure Ord Shs (NVCR)
United Therapeutics Corporation (UTHR)
Praxis Precision Medicines I Com New (PRAX)
Vericel (VCEL)
Alkermes SHS (ALKS)
Biosante Pharmaceuticals (ANIP)
Globus Med Cl A (GMED)
Geron Corporation (GERN)
Twist Bioscience Corp (TWST)
Edgewise Therapeutics (EWTX)
Beta Bionics (BBNX)

View all positions for Soleus Capital Management

Top funds holding Sab Biotherapeutics

Vivo Capital
Perceptive Advisors
Commodore Capital
RA Capital Management
Balyasny Asset Management
Millennium Management
Woodline Partners
Vanguard Capital Management
Sessa Capital IM
Vanguard Group
Boothbay Fund Management
Ameriprise Financial
Ensign Peak Advisors
Soleus Capital Management
Propel Bio Management

View all funds holding Sab Biotherapeutics